Preoperative CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels as prognostic indicators in resected non-small cell lung cancer

被引:11
作者
Foa, P
Fornier, M
Miceli, R
Seregni, E
Santambrogio, L
Nosotti, M
Massaron, S
Cataldo, I
Oldani, S
Iurlo, A
Caldiera, S
Bombardieri, E
机构
[1] Univ Milan, Ist Sci Med, I-20122 Milan, Italy
[2] Ist Nazl Studio & Cura Tumori, Div Stat Med & Biometria, Milan, Italy
[3] Ist Nazl Studio & Cura Tumori, Div Nucl Med, Milan, Italy
[4] Univ Studi, Ist Chirurg Sperimentale & Trapianti Organo, Milan, Italy
[5] Ist Nazl Studio & Cura Tumori, Div Chirurg Toracica, I-20133 Milan, Italy
关键词
non-small cell lung cancer; CEA; NSE; SCC; TPA; CYFRA; 21.1;
D O I
10.1177/172460089901400206
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
In 62 patients affected by resectable non-small cell lung cancer (NSCLC) submitted to radical surgery we evaluated the prognostic significance of CEA, NSE, SCC, TPA and CYFRA 21.1 serum levels at diagnosis, as well as the predictive ability of these tumor markers with respect to histological type and pathological stage. The group was composed of 56 male and 6 female patients; the median age was 62 years (range 29-73 years). Thirty-four patients had a histological diagnosis of adenocarcinoma and 28 of squamous cell carcinoma; with regard to pathological stage, 32 patients had stage I, 4 patients stage II and 23 patients stage IIIA disease. A good predictive ability with respect to histological type was obtained with SCC serum levels; as for pathological stage, TPA and CYFRA 21.1 were found to have moderate predictive ability. In this series of patients, at a median follow-up of 55 months after surgery, we found that both TPA and CYFRA 21.1 serum levels at diagnosis were reliable predictors of overall survival, high values of these markers being associated with a worse prognosis.
引用
收藏
页码:92 / 98
页数:7
相关论文
共 41 条
[1]   CLINICAL USEFULNESS OF SERUM ASSAYS OF NEURON-SPECIFIC ENOLASE, CARCINOEMBRYONIC ANTIGEN AND CA-50 ANTIGEN IN THE DIAGNOSIS OF LUNG-CANCER [J].
BERGMAN, B ;
BREZICKA, FT ;
ENGSTROM, CP ;
LARSSON, S .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (02) :198-202
[2]   USEFULNESS OF TISSUE POLYPEPTIDE ANTIGEN IN STAGING, MONITORING, AND PROGNOSIS OF LUNG-CANCER [J].
BUCCHERI, G ;
FERRIGNO, D .
CHEST, 1988, 93 (03) :565-570
[3]   PROGNOSTIC VALUE OF THE TISSUE POLYPEPTIDE ANTIGEN IN LUNG-CANCER [J].
BUCCHERI, G ;
FERRIGNO, D .
CHEST, 1992, 101 (05) :1287-1292
[4]  
BUCCHERI GF, 1987, CANCER, V60, P42, DOI 10.1002/1097-0142(19870701)60:1<42::AID-CNCR2820600109>3.0.CO
[5]  
2-3
[6]  
CARNEY DN, 1982, LANCET, V1, P583
[7]  
DEANGELIS G, 1988, J TUMOR MARKER ONCOL, V3, P15
[8]  
DEVINE PL, 1994, INT J ONCOL, V4, P1129
[9]  
EBERT W, 1994, EUR J CLIN CHEM CLIN, V32, P189
[10]  
ERBERT W, 1992, DIAGN ONCOL, V2, P203